All trials reported data on visual acuity ranging from three weeks to one year, and none of them found any important difference between the corticosteroid group and the control group . The pilot study of the SCUT reported that time to re-epithelialization in the steroid group was 53% slower than the placebo group after adjusting for baseline epithelial defect size (hazard ratio (HR) ; 95% confidence interval ( CI ) to ). However, the SCUT did not find any important difference in time to re-epithelialization (HR ; 95% CI to ). For adverse events, none of the three small trials found any important difference between the two treatment groups. The investigators of the largest trial reported that more patients in the control group developed intraocular pressure (IOP) elevation ( risk ratio ( RR ) ; 95% CI to ). One trial reported quality of life and concluded that there was no difference between the two groups ( data not available). We did not find any reports regarding economic outcomes.
Lotemax is used in dry eye syndrome to decrease and eliminate inflammation of the ocular surface caused by the hyperosmolarity of the tears. The inflammation must first be brought under control before any other treatments can be optimally effective. Lotemax would typically be prescribed for two weeks to three months initially and then may need to be used again on a 1-2 week regimen periodically if the inflammation occurs again. Lotemax ointment has become a choice of many doctors to treat inflammation caused by dry eye (ocular surface disease) because it can be used at night with a long contact period to the eye's surfaces and provide some functional lubrication while the eyes are closed.